Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
600196 On Other Exchanges
Symbol
Exchange
600196 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

shanghai fosun pharmaceuti-a (600196) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SHANGHAI FOSUN PHARMACEUTI-A (600196)

Related News

No related news articles were found.

shanghai fosun pharmaceuti-a (600196) Related Businessweek News

No Related Businessweek News Found

shanghai fosun pharmaceuti-a (600196) Details

Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a healthcare company, engages in the research, development, production, trade, and sale of pharmaceutical products in Mainland China and internationally. The company offers metabolism and alimentary tract drugs for the treatment of chronic hepatitis B, diabetes, chronic atrophic gastritis and gastralgia, flatulence, anorexia, eructation, and pyrosis; and anti-infection drugs to treat malaria, cefmetazole sodium sensitive bacterial infections, tuberculosis, sensitive gram-positive bacterial infections, and viral pneumonia and upper respiratory tract infections. It also provides cardiovascular and blood system drugs for antithrombotic treatment, ductus dependent congenital heart diseases, hypoxaemia relief, and chronic hepatitis; and the treatment of myocarditis, sinus syndrome, coronary heart disease, cardiomyopathy, arrhythmia, hypertension, microangiopathy, varicose veins syndrome, microcirculatory disorders, hypercholesterolemia, anemia, and chronic renal failure, as well for various dialysis treatments. In addition, the company offers oncology drugs for the treatment of lung, breast, prostate, gastric, colorectal, and nasopharyngeal cancers, as well as for malignant pleural mesothelioma; and vaccines for the prevention of influenza. Further, it provides central nervous system drugs; and crude drugs and intermediates. Additionally, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, imports, exports, and sells medical equipment and diagnostic products; provides healthcare and hospital management services, and consulting services; and manufactures and sells biologic pharmaceutical products. The company was formerly known as Shanghai Fosun Industrial Co. Ltd. and changed its name to Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in December 2004. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.

Founded in 1994

shanghai fosun pharmaceuti-a (600196) Top Compensated Officers

Vice Chairman, Chief Executive Officer, Presi...
Total Annual Compensation: CNY4.6M
Executive Chairman, Chairman of Strategic Com...
Total Annual Compensation: CNY6.4M
Compensation as of Fiscal Year 2014.

shanghai fosun pharmaceuti-a (600196) Key Developments

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Reports Unaudited Consolidated and Parent Earnings Results for the First Quarter Ended March 31, 2015

Shanghai FOSUN Pharmaceutical (Group) Co., Ltd. reported unaudited consolidated and parent earnings results for the first quarter ended March 31, 2015. On consolidated basis, total operating revenue was RMB 2,800,295,839.93 compared to RMB 2,657,829,657.86 a year ago. Operating profit was RMB 703,885,515.56 compared to RMB 543,229,569.96 a year ago. Total profit was RMB 717,692,682.89 compared to RMB 547,385,786.92 a year ago. Net profit attributable to the owners of the parent company was RMB 536,355,998.91 or RMB 0.23 per basic and diluted share compared to RMB 415,708,966.54 or RMB 0.19 per basic and diluted share a year ago. Net cash flow arising from operating activities was RMB 182,986,830.27 against RMB 7,028,518.43 last year. Cash paid for acquisition of fixed assets, intangible assets and other long-term assets was RMB 272,325,601.76 against RMB 363,953,694.84 last year. Weighted average return on net assets was 3.13% compared to 2.66% last year. On parent basis, operating profit was RMB 327,460,559.20 compared to operating loss of RMB 1,023,379.44 a year ago. Total profit was RMB 327,535,559.20 compared to total loss of RMB 1,208,379.44 a year ago. Net profit was RMB 327,535,559.20 compared to net loss of RMB 1,208,379.44 a year ago. Net cash flow used in operating activities was RMB 45,990,040.89 against RMB 47,048,872.94 last year. Cash paid for acquisition of fixed assets, intangible assets and other long-term assets was RMB 106,222.21 against nil in last year.

Shanghai FOSUN Pharmaceutical (Group) Co., Ltd., Board Meeting, Apr 16, 2015

Shanghai FOSUN Pharmaceutical (Group) Co., Ltd., Board Meeting, Apr 16, 2015. Agenda: To discuss and approve issues including the proposal of scheme of non-public A shares issuance, the proposal of signing agreement on contract on shares subscription with collateral entry-into-force conditions with China Life Insurance Company Limited, China Merchants Property Asset Management Limited, Taikang Asset Management Co., Ltd., China Fund Management Co., Ltd., China Universal Asset Management Co., Ltd., Anhui Railway Construction Investment Fund Co., Ltd., Beijing Zhongrong Dingxin Investment Management Co., Ltd. and Elion Resources Group and the proposal of amending Articles of Association.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Proposes Amendments to its Articles of Association

Shanghai FOSUN Pharmaceutical (Group) Co., Ltd. announced that the board proposed amendments to Article 228 of the Articles of Association in respect of the profit distribution policy and the related decision-making procedures and mechanism.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600196:CH CNY27.51 CNY +0.11

600196 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bangkok Dusit Medical Services PCL 20.20 THB -0.20
Bumrungrad Hospital PCL 160.50 THB +1.50
IHH Healthcare Bhd 5.92 MYR -0.08
KPJ Healthcare Bhd 4.26 MYR 0.00
Ramsay Health Care Ltd A$62.51 AUD -0.08
View Industry Companies
 

Industry Analysis

600196

Industry Average

Valuation 600196 Industry Range
Price/Earnings 28.7x
Price/Sales 5.3x
Price/Book 3.7x
Price/Cash Flow 23.5x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHANGHAI FOSUN PHARMACEUTI-A, please visit www.fosunpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.